Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Free Report) – Equities research analysts at Roth Capital issued their Q1 2025 EPS estimates for Chemomab Therapeutics in a research note issued on Friday, June 21st. Roth Capital analyst J. Wittes anticipates that the company will earn ($0.20) per share for the quarter. The consensus estimate for Chemomab Therapeutics’ current full-year earnings is ($0.90) per share. Roth Capital also issued estimates for Chemomab Therapeutics’ Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS and Q4 2025 earnings at ($0.20) EPS.
A number of other equities analysts have also issued reports on CMMB. Oppenheimer upgraded shares of Chemomab Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research report on Monday, May 6th. Maxim Group raised Chemomab Therapeutics to a “strong-buy” rating in a research note on Friday, May 24th.
Chemomab Therapeutics Stock Up 2.1 %
Shares of Chemomab Therapeutics stock opened at $1.02 on Monday. The firm has a market capitalization of $11.27 million, a P/E ratio of -0.64 and a beta of 0.48. Chemomab Therapeutics has a 52 week low of $0.42 and a 52 week high of $1.50. The firm’s 50 day moving average is $0.88 and its two-hundred day moving average is $0.72.
Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08).
Chemomab Therapeutics Company Profile
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
See Also
- Five stocks we like better than Chemomab Therapeutics
- How to Invest in Biotech Stocks
- Chipotle Mexican Grill Stock Split: Where Does it Go From Here?
- Canada Bond Market Holiday: How to Invest and Trade
- Arm Holdings and Micron: Top 2 AI Stocks to Buy and Hold
- Election Stocks: How Elections Affect the Stock Market
- Best Buy Stock May Be Best Bought Before the Holiday Season
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.